Looking Back at Cannabis Research

Author: Mechoulam, R.

Source: Current Pharmaceutical Design, Volume 6, Number 13, 1 September 2000 , pp. 1313-1322(10)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Research leading to the isolation of the plant cannabinoids during the 1960s and to the endogenous cannabinoids, during the 1990s is described. Investigations on two non-psychotropic, synthetic cannabinoids, HU-211, a neuroprotective agent and HU-308, a specific CB 2 agonist are presented.

Keywords: Cannabis; Plant cannabinoids; Endogenous cannabinoids; Non-psychotropic; Synthetic cannabinoids; HU-211; Neuroprotective; HU-308; CB2 agonist; Cannabidiol (CBD); Spectroscopy; NMR; Cannabinoids; Geranyl pyrophosphate; Cannabigerol; Cannabigerolic acid; Cannabidiol; Cannabidiolic acid; Cannabichromene; Cannabichromenic acid; Cannabielsoic acid A; Cannabinolic acid; Cannabinol; Cannabicylol; D9-THC; D8-THC; Anandamide; 2-arachidonoyl-glycerol (2-AG); HU-211 (DEXANABINOL); HU-211; NMDA receptor; HU-211 DRUG DEVELOPMENT; HU-308; Synthesis of HU-308; APPETITE; AIDS; commercial name dronabinol

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612003399509

Publication date: 2000-09-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.